Pilot Trial of Visual Healing in Psilocybin-assisted Therapy for Alcohol Use Disorder
Open-label, randomised, Phase II pilot RCT (n=20) comparing psilocybin 25 mg with Visual Healing versus standard set and setting in adults with moderate–severe alcohol use disorder to assess feasibility, safety and tolerability.
Details
This randomised, open-label, parallel-group pilot trial assigns 20 adults with moderate–severe alcohol use disorder to psilocybin 25 mg plus the Visual Healing set-and-setting platform or psilocybin 25 mg with standard set-and-setting to evaluate feasibility, safety, and tolerability.
Participants receive an initial psilocybin session (25 mg) with assigned set-and-setting and preparatory and integration counselling; four weeks later all participants receive a second 25 mg session where they may choose Visual Healing or standard procedures. Outcomes focus on adverse events, retention, and feasibility metrics.